SynthesisBrain and behavior2026
Comparative Efficacy and Safety of Treatments for Parkinson's Disease With Depression: A Systematic Review and Bayesian Model-Based Network Meta-Analysis.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveDepression is a common non-motor symptom of Parkinson's disease (PD) and substantially impairs patients' quality of life. This study aimed to compare the efficacy and safety of different interventions for depression in PD.
methodsWe conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials (RCTs) in patients with PD and depression. Databases were searched from inception to September 30, 2025. Treatment effects were estimated using standardized mean differences (SMDs) for efficacy and odds ratios (ORs) for safety. Surface Under the Cumulative Ranking Curve (SUCRA) values were used to rank interventions. The protocol was registered in PROSPERO (CRD420251245403).
resultsThis study included 51 RCTs involving 5100 patients and 42 intervention measures. Compared with placebo, citalopram (SMD = -0.99, 95% CI: -1.87 to -0.12) and primary motor cortex (M1) repetitive transcranial magnetic stimulation (rTMS) (SMD = -1.29, 95% CI: -1.93 to -0.64) significantly improved depressive symptoms with moderate-quality evidence. SUCRA rankings favored citalopram (0.831), M1 rTMS (0.825), pergolide (0.811), and supplementary motor area (SMA) + M1 rTMS (0.802), although rankings should be interpreted alongside direct statistical comparisons. Several treatments could not be included in the safety network because of insufficient connectivity. Citalopram, sertraline, rasagiline, methylphenidate, memantine, and trazodone were associated with higher withdrawal rates due to adverse events.
conclusionOur findings indicate that selective serotonin reuptake inhibitors (SSRIs), dopamine agonists, and rTMS suggest relative efficacy and an acceptable safety profile in treating PD with depression. However, given the limited evidence for several interventions, these findings should be interpreted cautiously and confirmed in larger, multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.